[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655111":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":25,"interventions":36,"overallOfficials":13,"centralContacts":45,"locations":13,"responsibleParty":51,"collaborators":55,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":13,"enrollmentInfo":72,"targetDuration":13,"studyType":75,"phases":76,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":84,"whyStopped":13,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":13},{"fullName":5,"class":6},"Region Skane","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"30-day survival","proportion of patients alive","30 days after the cardiac arrest",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"QUADRUPLE",[21,22,23,24],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[26,31],{"label":27,"type":28,"description":13,"interventionNames":29},"naloxone","ACTIVE_COMPARATOR",[30],"Drug: naloxone",{"label":32,"type":33,"description":13,"interventionNames":34},"placebo","PLACEBO_COMPARATOR",[35],"Drug: Placebo",[37,41],{"type":38,"name":27,"description":39,"armGroupLabels":40,"otherNames":13},"DRUG","2 mg naloxone administered intravenously or intraosseously",[27],{"type":38,"name":42,"description":43,"armGroupLabels":44,"otherNames":13},"Placebo","0.9% saline administered intravenously or intraosseously",[32],[46],{"name":47,"role":48,"phone":49,"phoneExt":13,"email":50},"Anna Lybeck, MD PhD","CONTACT","0771-11 14 44","anna.lybeck@med.lu.se",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Anna Lybeck","associate professor & senior consultant, anesthetics and intensive care",[56,58,61],{"name":57,"class":6},"Lund University",{"name":59,"class":60},"Clinical Studies Sweden - Forum South","UNKNOWN",{"name":62,"class":6},"Copenhagen Trial Unit, Center for Clinical Intervention Research","100655111","phase-2-naloxone-for-in-hospital-cardiac-arrest-100655111",false,"NCT07806565","Naloxone for In-Hospital Cardiac Arrest","naloxone-IHCA","Inclusion Criteria:\n\n1. In-Hospital Cardiac Arrest\n2. Age ≥ 18 years\n3. Received at least one dose of adrenaline during CPR\n\nExclusion Criteria:\n\n1. \"Do-not-resuscitate\"-order\n2. Known\u002Fsuspected pregnancy\n3. Known objection by the patient to participate in the trial\n4. Previous inclusion in the trial","ALL","18 Years",{"count":73,"type":74},850,"ESTIMATED","INTERVENTIONAL",[77,78],"PHASE2","PHASE3","The goal of this clinical trial is to learn if the drug naloxone in addition to cardiopulmonary resuscitation improves outcomes of in-hospital cardiac arrets. The main questions it aims to answer are:\n\nDoes naloxone improve survival after the cardiac arrest? Does naloxone improve functional outcome in survivors of cardiac arrest? Does naloxone improve health related quality of life after the cardiac arrest? How common are adverse reactions to naloxone when administered during cardiopulmonary resuscitation.\n\nResearchers will compare naloxone to a placebo (a look-alike substance that contains no drug) to see if naloxone works during cardiac arrest.",[81],"Heart Arrest",[27,83],"in-hospital cardiac arrest","NOT_YET_RECRUITING","2026-09-01",{"date":87,"type":88},"2026-09-08","ACTUAL",{"date":90,"type":74},"2027-01-01",{"date":92,"type":74},"2031-07-01",{"name":5,"class":6}]